<?xml version="1.0" encoding="UTF-8"?>
<p>Finally, we suggest that serum creatinine and urinary abnormalities should be monitored with accuracy in all patients after antiviral treatment with DAAs. Newâ€“onset or relapsing glomerular disease has been noted by some authors in patients who achieved SVR with regimens based on DAAs [
 <xref rid="B18-pathogens-08-00176" ref-type="bibr">18</xref>,
 <xref rid="B19-pathogens-08-00176" ref-type="bibr">19</xref>,
 <xref rid="B20-pathogens-08-00176" ref-type="bibr">20</xref>]. 
 <xref ref-type="fig" rid="pathogens-08-00176-f002">Figure 2</xref> shows purpuric manifestations in the lower limbs in a patient with HCV-related cryogobulinemic patient who received DAAs. After DAAs, the patient obtained SVR but cryoglobulins remain detectable in serum. The patient suffered from frequent and spontaneous episodes of purpura over the observation period (i.e., three or four times a year). Purpura disappeared spontaneously in most cases.
</p>
